Yunpeng Ma

发表

CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy.

D. Gandara, R. O’Donnell, D. Pearson, 2012, Cancer research.

Anti-CD 22 Monoclonal Antibody Enhances Bortezomib-mediated Lymphomacidal Activity in a Sequence Dependent Manner Permalink

Donnell, H. McKnight, J. Tuscano, 2012 .

The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner

R. O’Donnell, H. McKnight, J. Tuscano, 2011, Journal of hematology & oncology.

Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)

R. O’Donnell, J. Tuscano, W. Zamboni, 2009, Investigational New Drugs.

The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone

R. O’Donnell, J. Tuscano, J. Kato, 2011, Cancer Immunology, Immunotherapy.

Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts

R. O’Donnell, D. Pearson, H. McKnight, 2009, Cancer Immunology, Immunotherapy.

The Bispecific Anti-CD20/CD22 Antibody (Bs20x22) Has More Lymphomacidal Activity Than the Parent Antibodies Both Alone or In Combination

J. Tuscano, L. Newell, Yunpeng Ma, 2010 .

Efficacy, Biodistribution, and Pharmacokinetics of CD22-Targeted Pegylated Liposomal Doxorubicin in a B-cell Non–Hodgkin's Lymphoma Xenograft Mouse Model

J. Tuscano, W. Zamboni, Yunpeng Ma, 2010, Clinical Cancer Research.

Therapeutics , Targets , and Chemical Biology CD 22 Antigen IsBroadlyExpressedonLungCancerCells and Is a Target for Antibody-Based Therapy

D. Gandara, D. Pearson, J. Tuscano, 2012 .

A purified, fermented, extract of Triticum aestivum has lymphomacidal activity mediated via natural killer cell activation

J. Tuscano, Yunpeng Ma, G. Barisone, 2018, PloS one.

Unravelling the immune contexture of pre-invasive lesions of the lung by multispectral imaging

J. Galon, Mihaela Angelova, C. Mascaux, 2018 .